Regarding the CaV1.2-β protein interactions, Galectin-1, a member of β-galactoside-binding protein family (85), has been identified as a new CaV1.2-binding partner that interact with I–II loop in a splice isoform-specific and CaV1.2 channel-selective manner (86), and has emerged as a novel target for hypertension treatment through disrupting CaV1.2-β protein interaction and promoting the proteasomal degradation of CaV1.2 channels (87). This evidence concerns the gene CACNA1C and hypertensive disorder.